idebenone

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Freidreich's Ataxia

Conditions

Freidreich's Ataxia

Trial Timeline

Jun 1, 2007 → Jun 1, 2012

NCT ID

NCT00993967

About idebenone

idebenone is a phase 3 stage product being developed by Santhera Pharmaceuticals for Freidreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT00993967. Target conditions include Freidreich's Ataxia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03433807	Pre-clinical	Completed	—	—	Duchenne Muscular Dystrophy
NCT02771379	Pre-clinical	Completed	Sep 1, 2016	Apr 16, 2021	Leber's Hereditary Optic Neuropathy (LHON)
NCT02774005	Approved	Completed	May 1, 2016	Mar 29, 2021	Leber's Hereditary Optic Neuropathy (LHON)
NCT00758225	Phase 2	Completed	Sep 1, 2008	Jan 1, 2011	Duchenne Muscular Dystrophy
NCT00697073	Phase 3	Completed	Jul 1, 2008	May 1, 2010	Friedreich's Ataxia
NCT00993967	Phase 3	Completed	Jun 1, 2007	Jun 1, 2012	Freidreich's Ataxia

Other Products from Santhera Pharmaceuticals

vamorolone 40 mg/mL oral suspensionApproved

IdebenoneApproved

Placebo + IdebenonePhase 3

idebenone + PlaceboPhase 3

Idebenone + Idebenone + PlaceboPhase 3